Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

Emerging Risk Factors Collaboration, N Sarwar, P Gao, S R Kondapally Seshasai, R Gobin, S Kaptoge, E Di Angelantonio, E Ingelsson, D A Lawlor, E Selvin, M Stampfer, C D A Stehouwer, S Lewington, L Pennells, A Thompson, N Sattar, I R White, K K Ray, J Danesh, R W Tipping, C E Ford, S L Pressel, A R Folsom, L E Chambless, E Selvin, L E Wagenknecht, D B Panagiotakos, C Pitsavos, C Chrysohoou, C Stefanadis, M Knuiman, P H Whincup, S G Wannamethee, R W Morris, S Kiechl, J Willeit, F Oberhollenzer, A Mayr, N Wald, S Ebrahim, D A Lawlor, J W Yarnell, J Gallacher, E Casiglia, V Tikhonoff, P J Nietert, S E Sutherland, D L Bachman, J E Keil, I H de Boer, J R Kizer, K J Mukamal, A Tybjaerg-Hansen, B G Nordestgaard, M Benn, R Frikke-Schmidt, L Palmieri, S Panico, D Vanuzzo, L Pilotto, A Gómez de la Cámara, M A Rubio, L Simons, J McCallum, Y Friedlander, F G R Fowkes, A J Lee, J Taylor, J M Guralnik, C L Phillips, R Wallace, J M Guralnik, C L Phillips, D G Blazer, J M Guralnik, C L Phillips, C L Phillips, J M Guralnik, K-T Khaw, H Brenner, E Raum, H Müller, D Rothenbacher, J H Jansson, P Wennberg, A Nissinen, C Donfrancesco, S Giampaoli, V Salomaa, K Harald, P Jousilahti, E Vartiainen, M Woodward, R B D'Agostino, R S Vasan, C S Fox, M J Pencina, E Bladbjerg, T Jørgensen, L Møller, J Jespersen, R Dankner, A Chetrit, F Lubin, L Wilhelmsen, H Eriksson, K Svärdsudd, L Welin, A Rosengren, L Wilhelmsen, G Lappas, H Eriksson, C Björkelund, L Lissner, C Bengtsson, P Cremer, D Nagel, T E Strandberg, V Salomaa, R S Tilvis, T A Miettinen, R S Tilvis, T E Strandberg, Y Kiyohara, H Arima, Y Doi, T Ninomiya, B Rodriguez, J M Dekker, G Nijpels, C D A Stehouwer, E Rimm, J K Pai, S Sato, H Iso, A Kitamura, H Noda, U Goldbourt, K Nyyssönen, T-P Tuomainen, J T Salonen, D Deeg, J L Poppelaars, T W Meade, J A Cooper, B Hedblad, G Berglund, G Engström, W M M Verschuren, A Blokstra, M Cushman, A R Folsom, B M Psaty, S Shea, A Döring, W Koenig, C Meisinger, W Mraz, W M M Verschuren, A Blokstra, H Bas Bueno-de-Mesquita, L Wilhelmsen, A Rosengren, G Lappas, A Fletcher, L H Kuller, G Grandits, R Selmer, A Tverdal, W Nystad, R Gillum, M Mussolino, E Rimm, S Hankinson, J E Manson, J K Pai, V Salomaa, K Harald, P Jousilahti, E Vartiainen, J A Cooper, K A Bauer, K W Davidson, S Kirkland, J Shaffer, M R Korin, A Kitamura, S Sato, H Iso, I Holme, R Selmer, A Tverdal, W Nystad, P Ducimetiere, X Jouven, S J L Bakker, R T Gansevoort, H L Hillege, C J Crespo, M R Garcia Palmieri, P Amouyel, D Arveiler, A Evans, J Ferrières, H Schulte, G Assmann, R G Westendorp, B M Buckley, C J Packard, N Sattar, B Cantin, B Lamarche, J-P Després, G R Dagenais, E Barrett-Connor, D L Wingard, R Bettencourt, V Gudnason, T Aspelund, G Sigurdsson, B Thorsson, M Trevisan, J Witteman, I Kardys, M Breteler, A Hofman, H Tunstall-Pedoe, R Tavendale, G D O Lowe, M Woodward, B V Howard, Y Zhang, L Best, J Umans, Y Ben-Shlomo, G Davey-Smith, A Onat, G Hergenç, G Can, I Njølstad, E B Mathiesen, M L Løchen, T Wilsgaard, B Zethelius, U Risérus, C Berne, E Ingelsson, J M Gaziano, M Stampfer, P Ridker, J M Gaziano, P Ridker, H Ulmer, G Diem, H Concin, A Tosetto, F Rodeghiero, J E Manson, L Tinker, S Liu, B V Howard, I M Marmot, R Clarke, R Collins, A Fletcher, E Brunner, M Shipley, P Ridker, J Buring, J Shepherd, S M Cobbe, I Ford, M Robertson, A Marin Ibañez, E J M Feskens, D Kromhout, M Walker, S Watson, M Alexander, E Di Angelantonio, S Erqou, P Gao, R Gobin, P Haycock, S Kaptoge, S R Kondapally Seshasai, S Lewington, L Pennells, P L Perry, K K Ray, N Sarwar, A Thompson, S G Thompson, M Walker, S Watson, I R White, A M Wood, D Wormser, J Danesh, Emerging Risk Factors Collaboration, N Sarwar, P Gao, S R Kondapally Seshasai, R Gobin, S Kaptoge, E Di Angelantonio, E Ingelsson, D A Lawlor, E Selvin, M Stampfer, C D A Stehouwer, S Lewington, L Pennells, A Thompson, N Sattar, I R White, K K Ray, J Danesh, R W Tipping, C E Ford, S L Pressel, A R Folsom, L E Chambless, E Selvin, L E Wagenknecht, D B Panagiotakos, C Pitsavos, C Chrysohoou, C Stefanadis, M Knuiman, P H Whincup, S G Wannamethee, R W Morris, S Kiechl, J Willeit, F Oberhollenzer, A Mayr, N Wald, S Ebrahim, D A Lawlor, J W Yarnell, J Gallacher, E Casiglia, V Tikhonoff, P J Nietert, S E Sutherland, D L Bachman, J E Keil, I H de Boer, J R Kizer, K J Mukamal, A Tybjaerg-Hansen, B G Nordestgaard, M Benn, R Frikke-Schmidt, L Palmieri, S Panico, D Vanuzzo, L Pilotto, A Gómez de la Cámara, M A Rubio, L Simons, J McCallum, Y Friedlander, F G R Fowkes, A J Lee, J Taylor, J M Guralnik, C L Phillips, R Wallace, J M Guralnik, C L Phillips, D G Blazer, J M Guralnik, C L Phillips, C L Phillips, J M Guralnik, K-T Khaw, H Brenner, E Raum, H Müller, D Rothenbacher, J H Jansson, P Wennberg, A Nissinen, C Donfrancesco, S Giampaoli, V Salomaa, K Harald, P Jousilahti, E Vartiainen, M Woodward, R B D'Agostino, R S Vasan, C S Fox, M J Pencina, E Bladbjerg, T Jørgensen, L Møller, J Jespersen, R Dankner, A Chetrit, F Lubin, L Wilhelmsen, H Eriksson, K Svärdsudd, L Welin, A Rosengren, L Wilhelmsen, G Lappas, H Eriksson, C Björkelund, L Lissner, C Bengtsson, P Cremer, D Nagel, T E Strandberg, V Salomaa, R S Tilvis, T A Miettinen, R S Tilvis, T E Strandberg, Y Kiyohara, H Arima, Y Doi, T Ninomiya, B Rodriguez, J M Dekker, G Nijpels, C D A Stehouwer, E Rimm, J K Pai, S Sato, H Iso, A Kitamura, H Noda, U Goldbourt, K Nyyssönen, T-P Tuomainen, J T Salonen, D Deeg, J L Poppelaars, T W Meade, J A Cooper, B Hedblad, G Berglund, G Engström, W M M Verschuren, A Blokstra, M Cushman, A R Folsom, B M Psaty, S Shea, A Döring, W Koenig, C Meisinger, W Mraz, W M M Verschuren, A Blokstra, H Bas Bueno-de-Mesquita, L Wilhelmsen, A Rosengren, G Lappas, A Fletcher, L H Kuller, G Grandits, R Selmer, A Tverdal, W Nystad, R Gillum, M Mussolino, E Rimm, S Hankinson, J E Manson, J K Pai, V Salomaa, K Harald, P Jousilahti, E Vartiainen, J A Cooper, K A Bauer, K W Davidson, S Kirkland, J Shaffer, M R Korin, A Kitamura, S Sato, H Iso, I Holme, R Selmer, A Tverdal, W Nystad, P Ducimetiere, X Jouven, S J L Bakker, R T Gansevoort, H L Hillege, C J Crespo, M R Garcia Palmieri, P Amouyel, D Arveiler, A Evans, J Ferrières, H Schulte, G Assmann, R G Westendorp, B M Buckley, C J Packard, N Sattar, B Cantin, B Lamarche, J-P Després, G R Dagenais, E Barrett-Connor, D L Wingard, R Bettencourt, V Gudnason, T Aspelund, G Sigurdsson, B Thorsson, M Trevisan, J Witteman, I Kardys, M Breteler, A Hofman, H Tunstall-Pedoe, R Tavendale, G D O Lowe, M Woodward, B V Howard, Y Zhang, L Best, J Umans, Y Ben-Shlomo, G Davey-Smith, A Onat, G Hergenç, G Can, I Njølstad, E B Mathiesen, M L Løchen, T Wilsgaard, B Zethelius, U Risérus, C Berne, E Ingelsson, J M Gaziano, M Stampfer, P Ridker, J M Gaziano, P Ridker, H Ulmer, G Diem, H Concin, A Tosetto, F Rodeghiero, J E Manson, L Tinker, S Liu, B V Howard, I M Marmot, R Clarke, R Collins, A Fletcher, E Brunner, M Shipley, P Ridker, J Buring, J Shepherd, S M Cobbe, I Ford, M Robertson, A Marin Ibañez, E J M Feskens, D Kromhout, M Walker, S Watson, M Alexander, E Di Angelantonio, S Erqou, P Gao, R Gobin, P Haycock, S Kaptoge, S R Kondapally Seshasai, S Lewington, L Pennells, P L Perry, K K Ray, N Sarwar, A Thompson, S G Thompson, M Walker, S Watson, I R White, A M Wood, D Wormser, J Danesh

Abstract

Background: Uncertainties persist about the magnitude of associations of diabetes mellitus and fasting glucose concentration with risk of coronary heart disease and major stroke subtypes. We aimed to quantify these associations for a wide range of circumstances.

Methods: We undertook a meta-analysis of individual records of diabetes, fasting blood glucose concentration, and other risk factors in people without initial vascular disease from studies in the Emerging Risk Factors Collaboration. We combined within-study regressions that were adjusted for age, sex, smoking, systolic blood pressure, and body-mass index to calculate hazard ratios (HRs) for vascular disease.

Findings: Analyses included data for 698 782 people (52 765 non-fatal or fatal vascular outcomes; 8.49 million person-years at risk) from 102 prospective studies. Adjusted HRs with diabetes were: 2.00 (95% CI 1.83-2.19) for coronary heart disease; 2.27 (1.95-2.65) for ischaemic stroke; 1.56 (1.19-2.05) for haemorrhagic stroke; 1.84 (1.59-2.13) for unclassified stroke; and 1.73 (1.51-1.98) for the aggregate of other vascular deaths. HRs did not change appreciably after further adjustment for lipid, inflammatory, or renal markers. HRs for coronary heart disease were higher in women than in men, at 40-59 years than at 70 years and older, and with fatal than with non-fatal disease. At an adult population-wide prevalence of 10%, diabetes was estimated to account for 11% (10-12%) of vascular deaths. Fasting blood glucose concentration was non-linearly related to vascular risk, with no significant associations between 3.90 mmol/L and 5.59 mmol/L. Compared with fasting blood glucose concentrations of 3.90-5.59 mmol/L, HRs for coronary heart disease were: 1.07 (0.97-1.18) for lower than 3.90 mmol/L; 1.11 (1.04-1.18) for 5.60-6.09 mmol/L; and 1.17 (1.08-1.26) for 6.10-6.99 mmol/L. In people without a history of diabetes, information about fasting blood glucose concentration or impaired fasting glucose status did not significantly improve metrics of vascular disease prediction when added to information about several conventional risk factors.

Interpretation: Diabetes confers about a two-fold excess risk for a wide range of vascular diseases, independently from other conventional risk factors. In people without diabetes, fasting blood glucose concentration is modestly and non-linearly associated with risk of vascular disease.

Funding: British Heart Foundation, UK Medical Research Council, and Pfizer.

Copyright 2010 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Hazard ratios (HRs) for vascular outcomes in people with versus those without diabetes at baseline Analyses were based on 530 083 participants. HRs were adjusted for age, smoking status, body-mass index, and systolic blood pressure, and, where appropriate, stratified by sex and trial arm. 208 coronary heart disease outcomes that contributed to the grand total could not contribute to the subtotals of coronary death or non-fatal myocardial infarction because there were fewer than 11 cases of these coronary disease subtypes in some studies. *Includes both fatal and non-fatal events.
Figure 2
Figure 2
Hazard ratios (HRs) for coronary heart disease and ischaemic stroke in people with versus those without diabetes at baseline, by individual characteristics HRs were adjusted as described in figure 1. BMI=body-mass index. *Bottom third=2 (mean 21·7 kg/m2); middle third=23·8–<27 kg/m2 (mean 25·3 kg/m2); and top third=≥27 kg/m2 (mean 30·7 kg/m2). †Bottom third=<123 mm Hg (mean 113 mm Hg); middle third=123–<141 mm Hg (mean 132 mm Hg); and top third=≥141 mm Hg (mean 157 mm Hg).
Figure 3
Figure 3
Hazard ratios (HRs) for coronary heart disease and ischaemic stroke in people with versus those without diabetes, progressively adjusted for baseline levels of conventional risk factors Analyses were based on 264 353 participants (11 848 cases) for coronary heart disease and 157 315 participants (2858 cases) for ischaemic stroke with complete information on all covariates listed. BMI=body-mass index.
Figure 4
Figure 4
Hazard ratios (HRs) for coronary heart disease and ischaemic stroke by baseline fasting blood glucose concentration Analyses were based on 279 290 participants (14 814 cases) for coronary heart disease (CHD) and 175 542 participants (1754 cases) for ischaemic stroke. Participants without known diabetes at baseline were classified into groups of fasting glucose (CHD: 7·5 mmol/L; ischaemic stroke: 7·0 mmol/L). HRs were adjusted as described in figure 1 and are plotted against mean fasting blood glucose in each group. Reference group for both outcomes is 5·0–5·5 mmol/L.
Figure 5
Figure 5
Hazard ratios (HRs) for coronary heart disease by clinically defined categories of baseline fasting blood glucose concentration Analyses were based on 279 290 participants (14 814 cases). HRs were adjusted as described in figure 1. HR (95% CI) in people with fasting glucose 5·60–6·99 mmol/L was 1·12 (1·06–1·18). *Reference group.
Figure 6
Figure 6
Comparison of hazard ratios (HRs) for coronary heart disease by long-term average concentrations of fasting blood glucose concentration, total (and non-HDL) cholesterol, and systolic blood pressure, in a common set of participants Analyses were done in participants with no known history of diabetes at baseline. Analyses of fasting blood glucose concentration, total cholesterol, and systolic blood pressure were based on 140 624 participants (10 667 cases). For fasting blood glucose, participants were classified into groups of baseline fasting concentrations, as described in figure 4. For the other factors presented, participants were classified according to baseline values as follows: total cholesterol,

References

    1. Spencer EA, Pirie KL, Stevens RJ. Diabetes and modifiable risk factors for cardiovascular disease: the prospective Million Women Study. Eur J Epidemiol. 2008;23:793–799.
    1. Schramm TK, Gislason GH, Kober L. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117:1945–1954.
    1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73–78.
    1. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med. 2002;162:1737–1745.
    1. Woodward M, Zhang X, Barzi F. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care. 2003;26:360–366.
    1. Janghorbani M, Hu FB, Willett WC. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study. Diabetes Care. 2007;30:1730–1735.
    1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–2581.
    1. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233–240.
    1. Lawes CM, Parag V, Bennett DA. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care. 2004;27:2836–2842.
    1. Helfand M, Buckley DI, Freeman M. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:496–507.
    1. Emerging Risk Factors Collaboration Analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007;22:839–869.
    1. Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000.
    1. Emerging Risk Factors Collaboration Statistical methods for time-to-event analysis of individual participant data from multiple epidemiological studies. Int J Epidemiol. 2010 published online May 3.
    1. Easton DF, Peto J, Babiker AG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med. 1991;10:1025–1035.
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
    1. Fibrinogen Studies Collaboration Measures to assess the prognostic ability of the stratified Cox proportional hazards model. Stat Med. 2009;28:389–411.
    1. Graubard BI, Flegal KM, Williamson DF. Estimation of attributable number of deaths and standard errors from simple and complex sampled cohorts. Stat Med. 2007;26:2639–2649.
    1. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J. 2007;28:88–136.
    1. Gan D, editor. Diabetes atlas. 3rd edn. International Diabetes Federation; Brussels: 2007.
    1. Lopez A, Mathers C, Ezatt M. Global burden of disease and risk factors. World Bank and Oxford University Press; New York: 2006.
    1. Creager MA, Luscher TF, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108:1527–1532.
    1. Natali A, Vichi S, Landi P. Coronary atherosclerosis in Type II diabetes: angiographic findings and clinical outcome. Diabetologia. 2000;43:632–641.
    1. Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res. 2001;49:554–560.
    1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(supp 1):62–69.
    1. Avendano M, Mackenbach JP. Blood glucose levels: facing a global crisis. Lancet. 2006;368:1631–1632.
    1. Danaei G, Lawes CM, Vander HS. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet. 2006;368:1651–1659.
    1. Kelly T, Yang W, Chen C-S. Global burden of obesity in 2005 and projections to 2030. Intl J Obes. 2008;32:1431–1437.
    1. Gao W, Qiao Q, Tuomilehto J. Post-challenge hyperglycaemia rather than fasting hyperglycaemia is an independent risk factor of cardiovascular disease events. Clin Lab. 2004;50:609–615.
    1. Sarwar N, Aspelund T, Eiriksdottir G. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PloS Med. 2010;7:e1000278.
    1. Sarwar N, Sattar N, Gudnason V, Danesh J. Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. Eur Heart J. 2007;249:1–7.

Source: PubMed

3
S'abonner